Search details
1.
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.
Blood
; 141(17): 2075-2084, 2023 04 27.
Article
in English
| MEDLINE | ID: mdl-36564047
2.
Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
Oncologist
; 28(6): 520-530, 2023 06 02.
Article
in English
| MEDLINE | ID: mdl-36971492
3.
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
Oncologist
; 27(10): 864-873, 2022 10 01.
Article
in English
| MEDLINE | ID: mdl-35948003
4.
Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma.
Blood
; 141(22): 2780-2783, 2023 06 01.
Article
in English
| MEDLINE | ID: mdl-36898084
5.
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Blood
; 132(25): 2639-2642, 2018 12 20.
Article
in English
| MEDLINE | ID: mdl-30266774
6.
Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
Adv Ther
; 40(5): 2326-2338, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36920744
7.
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.
Blood Adv
; 7(18): 5272-5280, 2023 09 26.
Article
in English
| MEDLINE | ID: mdl-37352266
8.
Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus.
Arch Pathol Lab Med
; 147(1): 79-86, 2023 01 01.
Article
in English
| MEDLINE | ID: mdl-35472771
9.
Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
J Med Econ
; 25(1): 324-333, 2022.
Article
in English
| MEDLINE | ID: mdl-35172685
10.
Health Care Resource Utilization and Costs Among Medicare Beneficiaries Newly Diagnosed With Peripheral T-cell Lymphoma: A Retrospective Claims Analysis.
Clin Lymphoma Myeloma Leuk
; 21(1): e1-e9, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33184000
11.
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Eur J Cancer
; 148: 411-421, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33794441
12.
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Blood Adv
; 5(23): 5098-5106, 2021 12 14.
Article
in English
| MEDLINE | ID: mdl-34507350
13.
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
Eur J Cancer
; 133: 120-130, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32502876
14.
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Blood Adv
; 8(10): 2400-2404, 2024 May 28.
Article
in English
| MEDLINE | ID: mdl-38531062
Results
1 -
14
de 14
1
Next >
>>